clinical trial · NCT05940402
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
AbbVie·phase1·completed·n = 58
Renal ImpairmentEmraclidine
brief summary
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.
started
Jul 24, 2023
primary completion
Dec 19, 2024
completion
Dec 19, 2024
last updated
Apr 4, 2025
official title
A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Renal Impairment Compared With Adult Participants With Normal Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol